Back to News
Market Impact: 0.3
Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Novartis said its ASTRALS Phase 2 trial of VHB937 for amyotrophic lateral sclerosis failed to meet both primary and secondary endpoints. The company will discontinue development of the investigational ALS therapy, eliminating the program from its pipeline and creating a negative read-through for the asset.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
NVS-0.85
More News
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist